Four-color flow cytometric analysis of myeloma plasma cells

被引:14
作者
Kobayashi, Shoichi
Hyo, Rie
Amitani, Yukiko
Tanaka, Masatsugu
Hashimoto, Chizuko
Sakai, Rika
Tamura, Takeshi
Motomura, Shigeki
Maruta, Atsuo
机构
[1] Kanagawa Canc Ctr, Div Clin Lab, Asahi Ku, Yokohama, Kanagawa 2410815, Japan
[2] Kanagawa Canc Ctr, Dept Hematol, Yokohama, Kanagawa, Japan
[3] Kanagawa Canc Ctr, Dept Chemotherapy, Yokohama, Kanagawa, Japan
关键词
multiple myelonna; four-color flow cytonnetric analysis; immunofixation;
D O I
10.1309/VWXARAAG9DAPQ31Y
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We monitored the behavior of residual myeloma plasma cells inpatients with multiple myeloma after high-dose therapy and autologous or allogeneic transplantation using 3 methods of aflow cytometric technique using 4-color staining, immunofixation, and polymerase chain reaction approaches. We analyzed 17 cases by a relatively simple flow cytometric technique using CD38/CD45/CD19/CD56 Detectable myeloma plasma cells were found in 5 patients at diagnosis and 9 patients after treatment. Of 14 cases, 9 (64%) had CD19-CD56+ myeloma plasma cells, and 5 (36%) of 14 had CD19-CD56- myeloma plasma cells. When 37 bone marrow samples that had less than 5% myeloma plasma cells were assessed, myeloma plasma cells were detected in all 20 immunofixation-positive cases and 3 of 17 immunofixation-negative cases (P=.002). All 4 polymerase chain reaction-negative samples characterized as immunofixation-negative contained no detectable myeloma plasma cells. Flow cytometry can provide effective information to detect low levels of myeloma plasma cells.
引用
收藏
页码:908 / 915
页数:8
相关论文
共 14 条
[1]   Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions [J].
Bayer-Garner, IB ;
Sanderson, RD ;
Dhodapkar, MV ;
Owens, RB ;
Wilson, CS .
MODERN PATHOLOGY, 2001, 14 (10) :1052-1058
[2]  
Billadeau D, 1996, BLOOD, V88, P289
[3]  
Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x
[4]   Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma [J].
Dahl, IMS ;
Rasmussen, T ;
Kauric, G ;
Husebekk, A .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) :273-277
[5]   The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma [J].
Davies, FE ;
Forsyth, PD ;
Rawstron, AC ;
Owen, RG ;
Pratt, G ;
Evans, PAS ;
Richards, SJ ;
Drayson, M ;
Smith, GM ;
Selby, PJ ;
Child, JA ;
Morgan, GJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) :814-819
[6]  
Sarasquete ME, 2005, HAEMATOLOGICA, V90, P1365
[7]  
HARADA H, 1993, BLOOD, V81, P2658
[8]   Assessment of IgH PCR strategies in multiple myeloma [J].
Owen, RG ;
Johnson, RJ ;
Rawstron, AC ;
Evans, PA ;
Jack, A ;
Smith, GM ;
Child, JA ;
Morgan, GJ .
JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (08) :672-675
[9]   The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma [J].
Pellat-Deceunynck, C ;
Barillé, S ;
Jego, G ;
Puthier, D ;
Robillard, N ;
Pineau, D ;
Rapp, MJ ;
Harousseau, JL ;
Amiot, M ;
Bataille, R .
LEUKEMIA, 1998, 12 (12) :1977-1982
[10]   IMPROVED PCR METHOD FOR DETECTING MONOCLONAL IMMUNOGLOBULIN HEAVY-CHAIN REARRANGEMENT IN B-CELL NEOPLASMS [J].
RAMASAMY, I ;
BRISCO, M ;
MORLEY, A .
JOURNAL OF CLINICAL PATHOLOGY, 1992, 45 (09) :770-775